These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24633296)

  • 1. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
    Kumai T; Ishibashi K; Oikawa K; Matsuda Y; Aoki N; Kimura S; Hayashi S; Kitada M; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2014 May; 63(5):469-78. PubMed ID: 24633296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
    Shen L; Schroers R; Hammer J; Huang XF; Chen SY
    Cancer Immunol Immunother; 2004 May; 53(5):391-403. PubMed ID: 14624313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
    Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
    Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
    zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
    J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
    Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
    Zhou G; Ding ZC; Fu J; Levitsky HI
    J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
    Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
    Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.